MX2022013430A - Metodos para tratar el crecimiento celular anormal. - Google Patents
Metodos para tratar el crecimiento celular anormal.Info
- Publication number
- MX2022013430A MX2022013430A MX2022013430A MX2022013430A MX2022013430A MX 2022013430 A MX2022013430 A MX 2022013430A MX 2022013430 A MX2022013430 A MX 2022013430A MX 2022013430 A MX2022013430 A MX 2022013430A MX 2022013430 A MX2022013430 A MX 2022013430A
- Authority
- MX
- Mexico
- Prior art keywords
- kras
- methods
- cell growth
- abnormal cell
- treating abnormal
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 229940124647 MEK inhibitor Drugs 0.000 abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 2
- 102100030708 GTPase KRas Human genes 0.000 abstract 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 1
- 206010069755 K-ras gene mutation Diseases 0.000 abstract 1
- 229940126685 KRAS G12R Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102200006531 rs121913529 Human genes 0.000 abstract 1
- 102200006537 rs121913529 Human genes 0.000 abstract 1
- 102200006539 rs121913529 Human genes 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
- 102200006540 rs121913530 Human genes 0.000 abstract 1
- 102200006541 rs121913530 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015883P | 2020-04-27 | 2020-04-27 | |
| PCT/US2021/029435 WO2021222278A1 (en) | 2020-04-27 | 2021-04-27 | Methods of treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013430A true MX2022013430A (es) | 2022-11-14 |
Family
ID=78332185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013430A MX2022013430A (es) | 2020-04-27 | 2021-04-27 | Metodos para tratar el crecimiento celular anormal. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230201198A1 (enExample) |
| EP (1) | EP4142882A4 (enExample) |
| JP (1) | JP2023523323A (enExample) |
| KR (1) | KR20230011277A (enExample) |
| CN (1) | CN115916346A (enExample) |
| AU (1) | AU2021263742A1 (enExample) |
| BR (1) | BR112022021657A2 (enExample) |
| CA (1) | CA3175481A1 (enExample) |
| IL (1) | IL297650A (enExample) |
| MX (1) | MX2022013430A (enExample) |
| WO (1) | WO2021222278A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| CN118574825A (zh) * | 2022-02-28 | 2024-08-30 | 微境生物医药科技(上海)有限公司 | 作为fak抑制剂的化合物及其用途 |
| CN118973580A (zh) * | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| EP4531846A4 (en) * | 2022-06-03 | 2026-05-27 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2025010293A2 (en) * | 2023-07-03 | 2025-01-09 | Immuneering Corporation | Mek immune oncology inhibitor pharmaceutical compositions |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025261499A1 (zh) * | 2024-06-20 | 2025-12-26 | 上海科州药物股份有限公司 | 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102859355B (zh) * | 2009-08-24 | 2015-10-07 | 基因泰克公司 | 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性 |
| US20110118298A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2012061683A2 (en) * | 2010-11-05 | 2012-05-10 | Glaxosmithkline Llc | Methods for treating cancer |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| AU2016258192B2 (en) * | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| KR102811888B1 (ko) * | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| KR20220134522A (ko) * | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
-
2021
- 2021-04-27 AU AU2021263742A patent/AU2021263742A1/en active Pending
- 2021-04-27 IL IL297650A patent/IL297650A/en unknown
- 2021-04-27 WO PCT/US2021/029435 patent/WO2021222278A1/en not_active Ceased
- 2021-04-27 EP EP21797285.0A patent/EP4142882A4/en active Pending
- 2021-04-27 KR KR1020227037020A patent/KR20230011277A/ko not_active Ceased
- 2021-04-27 US US17/921,509 patent/US20230201198A1/en active Pending
- 2021-04-27 BR BR112022021657A patent/BR112022021657A2/pt unknown
- 2021-04-27 MX MX2022013430A patent/MX2022013430A/es unknown
- 2021-04-27 CA CA3175481A patent/CA3175481A1/en active Pending
- 2021-04-27 CN CN202180028579.0A patent/CN115916346A/zh active Pending
- 2021-04-27 JP JP2022565600A patent/JP2023523323A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4142882A1 (en) | 2023-03-08 |
| IL297650A (en) | 2022-12-01 |
| AU2021263742A1 (en) | 2022-09-22 |
| CA3175481A1 (en) | 2021-11-04 |
| KR20230011277A (ko) | 2023-01-20 |
| WO2021222278A1 (en) | 2021-11-04 |
| BR112022021657A2 (pt) | 2022-12-20 |
| US20230201198A1 (en) | 2023-06-29 |
| JP2023523323A (ja) | 2023-06-02 |
| CN115916346A (zh) | 2023-04-04 |
| EP4142882A4 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007084A (es) | Inhibidores de pan-kras de azaquinazolina. | |
| BR112022021657A2 (pt) | Métodos de tratamento de crescimento celular anormal | |
| JOP20250111A1 (ar) | مثبطات kras كبيرة الحلقة وطرق استخدامها | |
| MX2024010043A (es) | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas kras mutantes. | |
| Xu et al. | Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis | |
| Allen et al. | Surgical management of Merkel cell carcinoma | |
| Kadletz et al. | Extracapsular dissection versus superficial parotidectomy in benign parotid gland tumors: the Vienna Medical School experience | |
| Tabár et al. | Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs | |
| Coakley et al. | Postoperative antibiotics correlate with worse outcomes after appendectomy for nonperforated appendicitis | |
| Gunduz et al. | Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer | |
| MX2023000589A (es) | Terapia de combinacion para tratar el crecimiento celular anormal. | |
| BR112024002182A2 (pt) | Composições estabilizadas | |
| Sun et al. | Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis | |
| Harati et al. | Soft tissue sarcomas of the distal lower extremities: A single-institutional analysis of the prognostic significance of surgical margins in 120 patients | |
| CR20240296A (es) | Inhibidores parp1 | |
| Sakib et al. | Effect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysis | |
| PL1682126T3 (pl) | Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf | |
| MX2022006366A (es) | Terapia de combinacion que implica compuestos de diarilo macrociclico. | |
| Gonçalves et al. | Hypocalcemia in cancer patients: an exploratory study | |
| Sagheb et al. | Cervical metastases behavior of T1–2 squamous cell carcinoma of the tongue | |
| Liu et al. | Correlation between the pathology and clinical presentations in patients with adenoid cystic carcinoma of the external auditory canal | |
| BR112017027277A2 (pt) | ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula? | |
| MX2016013048A (es) | Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. | |
| Wisnivesky et al. | Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis | |
| Ul-Hassan et al. | Can 18F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer? |